Ingrid Seebauer
About Ingrid Seebauer
Ingrid Seebauer is a Manager of CTAs and Contract Administrators with extensive experience in project management and contract administration within the pharmaceutical industry.
Current Title: Manager CTAs and Contract Administrators
Ingrid Seebauer holds the position of Manager of CTAs and Contract Administrators at Bristol-Myers Squibb in New York, New York. This role capitalizes on her extensive experience in managing clinical trial agreements and overseeing contract administration within the pharmaceutical industry. Her managerial responsibilities likely include coordinating and negotiating agreements, ensuring compliance with regulatory requirements, and fostering collaboration among stakeholders.
Previous Roles: Experience in the Pharmaceutical Industry
Ingrid Seebauer has a robust background in the pharmaceutical industry, having served in various key roles. From 2001 to 2002, she worked at INC Research as a Project Manager, where she managed project timelines and deliverables. Prior to this, from 1995 to 2000, she was a Projektleiter at AstraZeneca, overseeing project implementation and resource allocation. These roles underline her extensive expertise in project management within the sector.
Education: Ludwig-Maximilians-Universität München
Ingrid Seebauer completed her education at Ludwig-Maximilians-Universität München. This academic background provided her with foundational knowledge and skills that have supported her career in the pharmaceutical industry. Studying at this prestigious institution likely equipped her with critical thinking and analytical abilities essential for project management and contract administration roles.
International Professional Experience
Ingrid Seebauer's professional experience in New York, New York, United States reflects her international exposure and adaptability. Working for Bristol-Myers Squibb, a major pharmaceutical company, in a global hub has likely enhanced her skills in navigating diverse regulatory environments and collaborating with international teams. Her time in New York signifies a significant phase in her career, contributing to her comprehensive understanding of the global pharmaceutical landscape.